doi: 10.5732/cjc.012.10285

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia

Christopher P. Guise, Alexandra M. Mowday, Amir Ashoorzadeh, Ran Yuan, Wan-Hua Lin, Dong-Hai Wu, Jeff B. Smaill, Adam V. Patterson, Ke Ding

Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

[Abstract] Hypoxia, a state of low oxygen, is a common feature of solid tumors and is associated with disease progression as well as resistance to radiotherapy and certain chemotherapeutic drugs. Hypoxic regions in tumors, therefore, represent attractive targets for cancer therapy. To date, five distinct classes of bioreactive prodrugs have been developed to target hypoxic cells in solid tumors. These hypoxia-activated prodrugs, including nitro compounds, N-oxides, quinones, and metal complexes, generally share a common mechanism of activation whereby they are reduced by intracellular oxidoreductases in an oxygen-sensitive manner to form cytotoxins. Several examples including PR-104, TH-302, and EO9 are currently undergoing phase II and phase III clinical evaluation. In this review, we discuss the nature of tumor hypoxia as a therapeutic target, focusing on the development of bioreductive prodrugs. We also describe the current knowledge of how each prodrug class is activated and detail the clinical progress of leading examples.

Chinese Journal of Cancer 2014, Volume: 33, Issue 2, Page: 80-86

[ PDF Full-text ]
[ Html full-text ](PubMed Central)
[ PubMed ]
[Google Scholar]

Cite this article

Christopher P. Guise, Alexandra M. Mowday, Amir Ashoorzadeh, Ran Yuan, Wan-Hua Lin, Dong-Hai Wu, Jeff B. Smaill, Adam V. Patterson, Ke Ding. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chin J Cancer. 2014, 33(2):80-86. doi:10.5732/cjc.012.10285


Export citations

EndNote